Aleva Neurotherapeutics
Switzerland - LausanneBiotechnology
Focus: Aleva Neurotherapeutics is a Swiss-based biotech company founded in 2022 specializing in deep brain stimulation (DBS) systems for neurological disorders. The company is in early-stage development with a focused pipeline targeting Parkinson's disease.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Aleva Neurotherapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Aleva Neurotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Deep Brain Stimulation System
Parkinson DiseaseClinical Trials (2)
NCT05795218directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential Tremor
N/AHelp build intelligence for Aleva Neurotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.